Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-releasing Peptide Receptor (GRPR)

Next Previous
Trial Profile

A Phase I/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-releasing Peptide Receptor (GRPR)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gallium 68 NeoBOMB1 (Primary) ; Lutetium-177 NeoBOMB1 (Primary)
  • Indications Advanced breast cancer; Gastrointestinal stromal tumours; Glioblastoma; Glioma; HER2 negative breast cancer; Lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Acronyms NeoRay
  • Sponsors Advanced Accelerator Applications

Most Recent Events

  • 23 Jan 2025 Status changed from recruiting to active, no longer recruiting.
  • 24 Apr 2024 The protocol has been amended to increase in number of Arms and study time frame endpoints with respective increase in study population.
  • 24 Apr 2024 Planned number of patients changed from 86 to 51.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top